美國《科學(xué)》雜志七次評出干細(xì)胞為21世紀(jì)，干細(xì)胞再生醫(yī)學(xué)有希望形成巨大的健康產(chǎn)業(yè)美總統(tǒng)第13505號行政令-干細(xì)胞科研的解禁令備忘錄（2009年3月11日）十大科學(xué)成果之一又一場醫(yī)療革命2015年,習(xí)近平總書記指出,“兩彈一星”、多復(fù)變函數(shù)論、陸相成油理論、人工合成牛胰島素等成就，高溫超導(dǎo)、中微子物理、量子反常霍爾效應(yīng)、納米科技、干細(xì)胞研究、人類基因組測序等基礎(chǔ)科學(xué)突破，為我國作為一個有世界影響的大國奠定了重要基礎(chǔ)。2009年,溫家寶總理指出：干細(xì)胞研究促進了再生醫(yī)學(xué)的發(fā)展,這是繼藥物治療、手術(shù)治療之后的又一場醫(yī)療革命，我們要力爭在干細(xì)胞研究的更多領(lǐng)域取得領(lǐng)先地位。

巨大的社會和經(jīng)濟效益預(yù)計干細(xì)胞市場在2025可達$4000億元。Onecell,OnedreamStemcellSelf-renewDifferentiationFormtissues&organsIndividualdevelopmentmaturationandageingDifferentiationWhatarestemcells?

什么是干細(xì)胞?Stemcells:unitsofdevelopment,unitsofregeneration,andunitsinevolution.WeissmanIL.Cell.100:157–68,2000.

干細(xì)胞:機體發(fā)育、再生和進化的單元DifferentiationPotencydefinitionofstemcells–干細(xì)胞分類Totipotent(全能)

stemcellscandifferentiateintoembryonicandextraembryoniccelltypes.Pluripotent(亞全能)stemcellsarethedescendantsoftotipotentcellsandcandifferentiateintonearlyallcells,i.e.cellsderivedfromanyofthethreegermlayer.Multipotent(多能)

stemcellscandifferentiateintoanumberofcelltypes,butonlythoseofacloselyrelatedfamilyofcells.Oligopotent

(寡能)stemcellscandifferentiateintoonlyafewcelltypes,suchaslymphoidormyeloidstemcells.]Unipotent(單能)

stemcellscanproduceonlyonecelltype,theirown,buthavethepropertyofself-renewal,whichdistinguishesthemfromnon-stemcellsInducedpluripotentstemcells–誘導(dǎo)多能干細(xì)胞間充質(zhì)干細(xì)胞(MSC)MesenchymalstemcellMesenchymalstromalcellsBlood–leukemia,anemia(AA,Fanconianemia),radiationinjuryImmunediseases–GVHD,SLE,SEVascular–Brainorheartinfarction,limbIschemiaNeural–SpinalCordInjury,Stroke,Parkinson’sdisease,Alzheimer'sDisease,Metabolic–Diabetes,liverdisordersSkeletal/Muscle–Osteoporosis,Cartilage,MusculardystrophyExcretory–Bladder/IncontinenceDermatology–Skininjury,mucosainjuryOphthalmology/Vision–retinaldisease…..Clinicalpotentialofstemcells–干細(xì)胞臨床用途

內(nèi)在因素環(huán)境因素DNA損傷腫瘤與干細(xì)胞干細(xì)胞衰老腫瘤組織衰老全身衰老機能衰老Relationamongstemcells,agingandcancer干細(xì)胞與衰老和腫瘤的關(guān)系免疫細(xì)胞治療是21世紀(jì)最前沿的腫瘤治療方法腫瘤自體細(xì)胞免疫療法適用于多種腫瘤，包括惡性黑色素瘤、前列腺癌、腎癌、膀胱癌、卵巢癌、結(jié)腸癌、直腸癌、乳腺癌、宮頸癌、肺癌、喉癌、鼻咽癌、胰腺癌、肝癌、胃癌等.實體瘤手術(shù)后防止復(fù)發(fā)，也可以用于多發(fā)性骨髓瘤、B淋巴瘤和白血病等血液系統(tǒng)惡性腫瘤的復(fù)發(fā)CAR-T:醫(yī)藥界的阿波羅11號

0-1010-20 20-30 30-4040-5050-60>60AGEINYEARSTOTALSTEMCELLS(LOGSCALE)THENUMBEROFSTEMCELLSDECREASESBYALOGFOREVERYDECADEOFLIFEAgingandstemcelllossandsenescenceThehallmarksofAging衰老的特征Cell,2013中國干細(xì)胞治療技術(shù)研究發(fā)展歷程Before19901991-20002001-20052006-20102011-2015骨髓造血干細(xì)胞血液造血干細(xì)胞骨髓MSC胎盤臍帶MSC脂肪干細(xì)胞血管干細(xì)胞其它組織干細(xì)胞胚胎干細(xì)胞誘導(dǎo)多能干細(xì)胞研究熱點研究點papernumberNeuralstemcellsSkinstemcellsVascularstemcellsIPScellsESCGlobal

2352982097677097999861737217USA

60222614421201845253411548China

20849217565611398922705Japan

17729188766666811243444Germany

1381113384717045302279UK

99889494143124002230France

82527212892682321282Italy

9339754275582198884Canada

73257562132442141352Korea

5662715213200227890Australia

4588400124100174863Publishedpapersondifferentstemcells(TOP10)Datacollectedfrom

and（by08.31.2015)

MSCtotalBonemarrowMSCCordMSCPlacentaMSCAdiposeMSCClinicaltrialGlobal362731390219696143530530USA7566254020380596106China6895347065397413110Japan243797355342375Germany2049728772619411Italy1811690744921811Korea17445601903734846UK10753763915592France9053222499019Canada76326042104611Australia6002081126457Datacollectedfrom

and（by08.31.2015)Publishedpapersonmesenchymalstemcells(TOP10)4/7/2025

Clinicalapplicationofstemcells-干細(xì)胞臨床應(yīng)用神經(jīng)系統(tǒng)疾病脊髓損傷SpinalCordInjury腦卒中Stroke腦癱CerebralPalsy肌萎縮側(cè)索硬化AmyotrophicLateralSclerosis帕金森病Parkinson’sDisease多發(fā)性硬化MultipleSclerosis老年性癡呆Alzheimer's

Disease免疫系統(tǒng)疾病系統(tǒng)性硬化Systemic

Sclerosis系統(tǒng)性紅斑狼瘡Systemic

Lupus

Erythematosus干燥綜合癥Sjogren's

Syndrome消化系統(tǒng)疾病肝硬化Liver

Cirrhosis克隆氏病Crohn's

Disease心血管系統(tǒng)疾病心肌梗死Myocardial

Infarction心肌缺血Myocardial

Ischemia動脈粥樣硬化Atherosclerosis血液系統(tǒng)病再生障礙性貧血AplasticAnemia移植物抗宿主病GVHD白血病Leukemia呼吸系統(tǒng)疾病肺支氣管發(fā)育不良Bronchopulmonary

Dysplasia肺氣腫Emphysema慢性支氣管炎Chronic

Bronchitis泌尿生殖系統(tǒng)疾病腎病Kidney

Transplant陽痿Erectile

Dysfunction運動系統(tǒng)疾病股骨頭壞死Osteonecrosis

of

the

Femoral

Head骨關(guān)節(jié)炎Osteoarthritis皮膚病燒傷Burn內(nèi)分泌系統(tǒng)疾病糖尿病Diabetes

Mellitus一、血液干細(xì)胞治療缺血性血管病舉例Critical

vascularischemiaisaglobalconcernwithlimitedtherapy

重度缺血性血管病是世界公認(rèn)的難治性疾病Canstemcelltherapybeanefficacytherapyforcriticalvascularischemia?骨髓和血液中含有血管干細(xì)胞

FirsttherapyofcriticallimbischemiawithautologousbloodstemcellsMorethan5000patientshavebeentreatedbythistherapyBloodstemcellsLocalinjectionAngiogenicAndanti-inflammationRepairedTissueLimbIschemiaBloodreperfusionOnepatientwithadvancedcriticallimbischemia(CLI)receivedthistreatment.ChinJHematol,2003.HanZCetal.,DiabetesCare,2005Asignificantimprovementofdiabeticmicroangiopathywasobserved.Noobviousadverseeffectwasobservedaftercelltherapy.骨髓與外周血干細(xì)胞治療下肢缺血的療效比較研究M-PBMNCBMMNC76recruited74recruited72patientsweretreated132ischemiclimbs(ABI<0.9)wereinjectedwithBM-MNC2excluded1excluded2patientsdiscontinuedduetoamputation73patientsassessedforprimaryoutcomeat12week75patientsweretreated138ischemiclimbs(ABI<0.9)wereinjectedwithM-PBMNC3patientsdiscontinuedduetoamputation69patientsassessedforprimaryoutcomeat12weekHuangPP,HanZC.ThrombHaemost,2007臨床試驗結(jié)果表明兩種療法均安全有效、簡單經(jīng)濟。外周血干細(xì)胞移植具有取材方便、可以多次使用等優(yōu)點下肢缺血患者采用標(biāo)準(zhǔn)化移植方案接受外周血或骨髓干細(xì)胞移植的臨床療效分析（多中心合作）發(fā)現(xiàn)PB-MNC（治療組76例）與骨髓單個核細(xì)胞（BM-MNC）移植（對照組74例）治療下肢缺血均有效，兩組總體臨床療效相比無顯著性差異。但兩組中糖尿病下肢缺血患者治療后踝壓指數(shù)（ABI）的增加值均顯著性低于無糖尿病下肢缺血患者（治療組p=0.037;對照組p=0.027在潰瘍愈合率和截肢手術(shù)率方面也是非糖尿病下肢缺血患者要顯著優(yōu)于糖尿病下肢缺血患者。理論上可以治療下肢缺血的細(xì)胞來源來源論文數(shù)病例數(shù)未截肢數(shù)避免截肢率外周血932236210894.27%臍帶3676394.02%臍帶血5322887.5%骨髓912211184183.27%脂肪111100%不同組織來源的干細(xì)胞治療下肢缺血的病例數(shù)統(tǒng)計發(fā)表在中文科技刊物的臨床研究結(jié)果(截至于2015.10.31)二、圍產(chǎn)期干細(xì)胞的研究:

圍產(chǎn)期干細(xì)胞庫,細(xì)胞產(chǎn)品及其臨床應(yīng)用

Perinatalstemcells:primitivestemcellslocatedintheorgansoffetusesFetalproperstemcellscomefromthetissueofthefetusproper,andaregenerallyobtainedafteranabortion.Thesestemcellsarenotimmortalbuthaveahighlevelofdivisionandaremultipotent.Extraembryonicstemcellscomefromplacenta,umbilicalcord,amnioticfluidandmembranes.Thesestemcellsareacquiredafterbirth,andarenotimmortalbuthaveahighlevelofcelldivision,andarepluripotentormultipotent.Placentastemcellbanking

andmedicaltherapiesStemcelltherapiesTissueandorganengineeringandtherapiesStemcelldifferentiationandexpansionStemcellbankingPlacentastemcellbanking

andmedicaltherapiesPlacentastemcellbanking

andmedicaltherapiesStemcellbankingStemcelldifferentiationandexpansionStemcellbankingStemcelltherapiesStemcelldifferentiationandexpansionStemcellbankingTissueandorganengineeringandtherapiesStemcelltherapiesStemcelldifferentiationandexpansionStemcellbankingTissueandorganengineeringandtherapiesStemcelltherapiesTissueandorganengineeringandtherapiesStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesPlacentastemcellbanking

andmedicaltherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesPlacentastemcellbanking

andmedicaltherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapiesPlacentastemcellbanking

andmedicaltherapiesStemcellbankingStemcelldifferentiationandexpansionStemcelltherapiesTissueandorganengineeringandtherapies治療用圍產(chǎn)期組織干細(xì)胞庫及其產(chǎn)品制備流程BullAcadNatlMed.2009;CellTransplant,2011;StemCellDev,2012;StemCellInt,2012Hanetal.Humanperinatalstemcellbanking:experiencesandperspectivesforregenerativemedicine.Science(suppl),2012Firstbankofperinatalmesenchymalstemcells

forclinicalusesestablishedin2005干細(xì)胞銀行-干細(xì)胞庫–干細(xì)胞藥房2025/4/7干細(xì)胞制品的安全性研究干細(xì)胞治療多種組織損傷的臨床前動物實驗Blooddisease: Haematologica,2006Vasculardisease: JCellBiochem,2007Heartdiseases: JCellBiochem,2009;AnnThoracSurg,2011Stroke: Transplantation,2009Cerebralhemorrhage:CellPhysiolBiochem.,2009Liverinjury:Cytotherapy,2009,2010MultipleSclerosis: MultScler.,2009Colitis: CellTransplant,2011Myastheniagravis: ScandJImmunol.2010Diabetes: JCellMolMed,2008；Diabetes，in

pressUveoretinitis: InvestOphthalmolVisSci.2011Acutelunginjury: CellPhysiolBiochem.,2011BeforecelltherapyaftercelltherapyPilotclinicaltrialofmesenchymalstemcells胎盤間充質(zhì)干細(xì)胞治療II型糖尿病MultScler.2009May;15(5):644-6（多發(fā)性硬化癥）

Before

OnemonthlateScience(suppl),2012自體圍產(chǎn)期干細(xì)胞共移植治療重癥再生障礙性貧血Theresultsobtainedfrom50patientstreatedindicatethatthisnewstrategyiseffectiveinimprovingdonorengraftmentandreducingsevereGVHD,whichwillprovideafeasibleoptionforthetherapyofhigh-riskhematologicmalignancy.造血干細(xì)胞與間充質(zhì)干細(xì)胞共移植治療難治性惡性血液病造血干細(xì)胞和間充質(zhì)干細(xì)胞移植治療重癥再障DatasuggestthatUC-MSCs,possiblythankstotheirpotentimmunosuppressiveeffectonallo-reactivehostTlymphocytesescapingthepreparativeregimen,reducetheriskofgraftfailureandsevereGVHDinhaplo-HSCT.

成體干細(xì)胞共移植救治放射損傷新技術(shù)的建立與應(yīng)用干細(xì)胞治療心臟病的給藥途徑及模式WuKH,HanZC.AgeingResRev.2011國內(nèi)外不同組織來源的細(xì)胞治療心臟病的病例數(shù)統(tǒng)計來源病例數(shù)有效病例數(shù)有效率骨髓MNC36936498.6%外周血MNC8484100%臍帶血MNC1079790.7%臍帶MSC151493.3%發(fā)表在中英文科技刊物的臨床研究結(jié)果(截至于2015.10.31)

干細(xì)胞凝膠外用治療難治性皮膚炎癥損傷1:359-72,2012.干細(xì)胞庫（資源保存）